Rigel Pharmaceuticals Inc. [RIGL] shares are down more than -14.29% this year and recently increased 0.18% or $0.38 to settle at $2.16. RIGL has a short ratio of 8.17. This implies that the market is currently less bullish on the outlook for RIGL.

On 9, July 2020, Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe. According to news published on Yahoo Finance, TAVLESSE initial launch in Germany and the U.K. by Grifols S.A.

Analyst Birdseye View:

The most recent analyst activity for Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] stock was on September 26, 2019, when it was Resumed with an Overweight rating from JP Morgan, which also raised its 12-month price target on the stock to $7. Before that, on November 15, 2019, Cantor Fitzgerald Recapitulated an Overweight rating and elevated its amount target to $5. On March 01, 2019, Cantor Fitzgerald Reiterated an Overweight rating and plunged its price target on this stock from $9 to $7. On August 27, 2018, Citigroup Initiated a Buy rating and increased its price target to $8.50. On May 02, 2018, Cantor Fitzgerald Reiterated an Overweight rating and increased its price target to $9. On December 21, 2017, Piper Jaffray Resumed an Overweight rating and boosted its amount on this stock to $6. On December 15, 2017, Cantor Fitzgerald Initiated an Overweight rating and boosted its target amount on this stock to $6. H.C. Wainwright elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.23 and a peak of $3.10. At the most recent market close, shares of Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] were valued at $2.16.


Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] most recently reported quarterly sales of 55.76 billion, which represented growth of 342.90%. This publicly-traded organization’s revenue is $363,730 per employee, while its income is -$410,393 per employee. This company’s Gross Margin is currently 99.10%, its Operating Margin is -28.90%, its Pretax Margin is -112.83, and its Net Margin is -112.83. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -46.67, -81.73, -69.09 and -69.42 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 40.29 and the whole liability to whole assets at 24.61. It shows enduring liability to the whole principal at 32.22 and enduring liability to assets at 0.20 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.89 points at 1st support level, the second support level is making up to 1.63. But as of 1st resistance point, this stock is sitting at 2.45 and at 2.75 for 2nd resistance point.

Rigel Pharmaceuticals Inc. [RIGL] reported its earnings at $0.13 per share in the fiscal quarter closing of 3/30/2020. The Analysts for Wall Street were expecting to report its earnings at $0.13/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 12/30/2019, the stated earnings were -$0.1 calling estimates for -$0.08/share with the difference of -0.02 depicting the surprise of -25.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] is 3.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.68. Now if looking for a valuation of this stock’s amount to sales ratio it’s 6.04 and it’s amount to book ratio is 6.68.